Trial · NCT02437136
Participant flow56
How many started, completed or left each group, period by period.
21 to 40 of 56
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Dose Escalation/Confirmation (Phase 1b) | COMPLETED | Phase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab | 0 | |
| Dose Escalation/Confirmation (Phase 1b) | NOT COMPLETED | Phase 1b (Dose Escalation): Entinostat 3 mg Weekly + Pembrolizumab | 4 | |
| Dose Escalation/Confirmation (Phase 1b) | NOT COMPLETED | Phase 1b (Dose Escalation): Entinostat 5 mg Weekly + Pembrolizumab | 0 | |
| Dose Escalation/Confirmation (Phase 1b) | NOT COMPLETED | Phase 1b (Dose Confirmation): Entinostat 5 mg Weekly + Pembrolizumab | 0 | |
| Dose Escalation/Confirmation (Phase 1b) | NOT COMPLETED | Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab | 0 | |
| Dose Escalation/Confirmation (Phase 1b) | NOT COMPLETED | Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab | 0 | |
| Dose Escalation/Confirmation (Phase 1b) | NOT COMPLETED | Phase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab | 0 | |
| Dose Escalation/Confirmation (Phase 1b) | NOT COMPLETED | Phase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab | 0 | |
| Expansion (Phase 2) | STARTED | Phase 1b (Dose Escalation): Entinostat 3 mg Weekly + Pembrolizumab | 0 | |
| Expansion (Phase 2) | STARTED | Phase 1b (Dose Escalation): Entinostat 5 mg Weekly + Pembrolizumab | 0 | |
| Expansion (Phase 2) | STARTED | Phase 1b (Dose Confirmation): Entinostat 5 mg Weekly + Pembrolizumab | 0 | |
| Expansion (Phase 2) | STARTED | Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab | 18 | |
| Expansion (Phase 2) | STARTED | Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab | 76 | |
| Expansion (Phase 2) | STARTED | Phase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab | 53 | |
| Expansion (Phase 2) | STARTED | Phase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab | 38 | |
| Expansion (Phase 2) | Received at Least 1 Dose of Study Drug | Phase 1b (Dose Escalation): Entinostat 3 mg Weekly + Pembrolizumab | 0 | |
| Expansion (Phase 2) | Received at Least 1 Dose of Study Drug | Phase 1b (Dose Escalation): Entinostat 5 mg Weekly + Pembrolizumab | 0 | |
| Expansion (Phase 2) | Received at Least 1 Dose of Study Drug | Phase 1b (Dose Confirmation): Entinostat 5 mg Weekly + Pembrolizumab | 0 | |
| Expansion (Phase 2) | Received at Least 1 Dose of Study Drug | Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab | 18 | |
| Expansion (Phase 2) | Received at Least 1 Dose of Study Drug | Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab | 76 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02437136/flow?page=2